Frost & Sullivan: New drug candidates hold tremendous promise for European HIV drugs market
Patients to benefit from potential for improved efficacy in less commonly used types of ARV therapies and one-pill-daily combination drugs
17-Apr-2013 -
The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market.
New analysis from Frost & Sullivan, Analysis of the European HIV Drugs Market, finds that the market earned ...
HIV
inhibitors